Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Flagstar Bank NA (FLG) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

Flagstar Bank NATrade
Zimmer Biomet Holdings IncTrade

Price performance (Past 24H)

Key statistics

Flagstar Bank NA vs Zimmer Biomet Holdings Inc — how do they compare? Flagstar Bank NA trades at $14.24 (market cap $5.89B), while Zimmer Biomet Holdings Inc trades at $95.7 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 3.1× Flagstar Bank NA's market cap, and Zimmer Biomet Holdings Inc pays the higher dividend (0.99%). Which is the better fit depends on your goals.

FLGZBH
Market Cap
$5.89B$18.55B
Sector
FinancialsHealth
52-Week High
$15.36$107.71
52-Week Low
$10.72$79.58
Dividend Yield
0.28%0.99%
Enterprise Value
$25.61B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Flagstar Bank NA

Flagstar Bank (FLG) trades at $14.285, up 1.96% today, with a bullish technical signal from moving averages and a consensus analyst price target of $16.85. Recent Q2 2026 earnings missed estimates, but the bank reported its third consecutive profitable quarter, supported by loan growth and cost controls. A $250 million share repurchase program and dividend payments reflect strong capital management, while proprietary technology initiatives aim to bolster long-term growth.

The outlook is cautiously optimistic, with potential upside from execution on strategic initiatives and valuation support from a low P/B ratio of 0.77. Risks include earnings volatility, competitive pressures in regional banking, and sensitivity to interest rate changes. Analyst sentiment is positive with no sell ratings, but investors should monitor fee income trends and credit quality.

Zimmer Biomet Holdings Inc

ZBH trades at $97.78, up 1.27% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and raised its 2026 outlook. Revenue growth remains steady at 4.8% year-over-year, though net income margin has moderated from 2023 peaks. Analyst consensus is a 'Buy' with a $103.56 price target, indicating modest upside potential from current levels.

The stock offers a balanced risk-reward profile with solid fundamentals and positive momentum, but faces headwinds from margin pressure and rising debt levels. Investors should weigh the strong institutional support and consistent earnings performance against competitive pressures and macroeconomic uncertainties affecting the medtech sector.

Returns comparison

Trailing returns across standard periods

About Flagstar Bank NA

Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.

Read more on FLG

About Zimmer Biomet Holdings Inc

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.

Read more on ZBH